Dexmedetomidine Versus Magnesium Sulfate as Adjuvants to Intraperitoneal Bupivacaine for Postoperative Analgesia After Elective Laparoscopic Cholecystectomy
NCT ID: NCT06879288
Last Updated: 2025-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
75 participants
INTERVENTIONAL
2023-07-01
2025-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adding Magnesium Sulfate or Dexmedetomidine to Bupivacaine in Oblique Subcostal Tap Block for Laparoscopic Cholecystectomy: a Randomized Double -Blind Controlled Study
NCT06743919
Intraperitoneal Dexamethasone vs Dexamethasone Plus Magnesium Sulphate for Pain Relief in Laparoscopic Cholecystectomy
NCT03643666
Magnesium Sulfate for TAP Analgesia During Laparoscopic Cholecystectomy
NCT02533284
Adding Magnesium Sulfate to Bupivacaine in Ultrasound Guided Paravertebral Block for Laparoscopic Cholecystectomy
NCT05099250
Comparison Between Dexmedetomidine and Fentanyl As an Adjuvant to Bupivacaine in the Paravertebral Nerve Block in Laparoscopic Cholecystectomy for Postoperative Analgesia: Randomized Comparative Clinical Trial.
NCT06752629
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Bupivacaine is indicated for local infiltration, peripheral nerve block, sympathetic nerve block, and epidural and caudal blocks. It is available mixed with a small amount of epinephrine to increase the duration of its action. It typically begins working within 15 minutes and lasts for 2 to 8 hours.
Dexmedetomidine is a selective alpha-2 (α2) adrenergic agonist known to have analgesic and sedative characteristics that can augment the duration of action of local anesthetics.
Magnesium is an N-methyl-D-aspartate receptor antagonist in addition to its effects on calcium influx. The anti-inflammatory and opioid-sparing effects make it a popular component of opioid free anaesthesia. It is extensively used for perioperative analgesia in a dose of 30- to 50-mg/kg intravascular bolus followed by a 10- to 15-mg/kg/h infusion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bupivacaine group
Patients received intraperitoneal bupivacaine only at the end of the operations.
Bupivacaine
Patients received intraperitoneal bupivacaine only at the end of the operations.
Dexmedetomidine group
Patients received intraperitoneal bupivacaine plus dexmedetomidine at the end of the operations.
Dexmedetomidine
Patients received intraperitoneal bupivacaine plus dexmedetomidine at the end of the operations.
Magnesium group
Patients received intraperitoneal bupivacaine plus magnesium sulfate at the end of the operations.
Magnesium sulfate
Patients received intraperitoneal bupivacaine plus magnesium sulfate at the end of the operations.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bupivacaine
Patients received intraperitoneal bupivacaine only at the end of the operations.
Dexmedetomidine
Patients received intraperitoneal bupivacaine plus dexmedetomidine at the end of the operations.
Magnesium sulfate
Patients received intraperitoneal bupivacaine plus magnesium sulfate at the end of the operations.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* American Society of Anesthesiologists (ASA) class I-III.
* Scheduled to undergo elective laparoscopic cholecystectomy.
Exclusion Criteria
* Body mass index ≥40.
* Allergy to the study drugs.
* Advanced cardiac, renal and hepatic diseases.
* Patients with peritoneal drain or peritoneal wash after surgery.
* Uncooperative patients.
* Chronic pain medications.
* Hypomagnesaemia or hypermagnesaemia.
21 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maha Mahmoud Rabee El Gazzar
Resident of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, El-Gharbia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
36264MS215/6/23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.